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Aim: To evaluate the cost-effectiveness of IDegLira versus basal-bolus therapy (BBT) with insu-
lin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes
in the UK.
Methods: A Microsoft Excel model was used to evaluate the cost-utility of IDegLira versus BBT
over a 1-year time horizon. Clinical input data were taken from the treat-to-target DUAL VII trial,
conducted in patients unable to achieve adequate glycaemic control (HbA1c <7.0%) with basal insu-
lin, with IDegLira associated with lower rates of hypoglycaemia and reduced body mass index (BMI)
in comparison with BBT, with similar HbA1c reductions. Costs (expressed in GBP) and event-related
disutilities were taken from published sources. Extensive sensitivity analyses were performed.
Results: IDegLira was associated with an improvement of 0.05 quality-adjusted life years
(QALYs) versus BBT, due to reductions in non-severe hypoglycaemic episodes and BMI with
IDegLira. Costs were higher with IDegLira by GBP 303 per patient, leading to an incremental
cost-effectiveness ratio (ICER) of GBP 5924 per QALY gained for IDegLira versus BBT. ICERs
remained below GBP 20 000 per QALY gained across a range of sensitivity analyses.
Conclusions: IDegLira is a cost-effective alternative to BBT with insulin glargine U100 plus insu-
lin aspart, providing equivalent glycaemic control with a simpler treatment regimen for patients
with type 2 diabetes inadequately controlled on basal insulin in the UK.
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cost, cost-effectiveness, diabetes mellitus, GLP-1 receptor agonist, hypoglycaemia, IDegLira,
insulin, UK
1 | INTRODUCTION
Diabetes is a well-characterised metabolic disorder known to affect
approximately 6.2% of the UK population, with 2.9 million people esti-
mated to have diabetes nationwide in 2015.1 Type 2 diabetes mellitus
accounts for approximately 90% of diabetes cases, and is primarily
caused by insulin resistance, with progressive beta-cell loss eventually
leading to insulin deficiency.2,3 Poor glycaemic control has been linked
to an increased risk of diabetes-related complications, including
retinopathy, nephropathy, autonomic nervous system malfunction,
diabetic foot (possibly requiring amputation) and increased risk of
stroke and myocardial infarction.4–11
The National Institute for Health and Care Excellence (NICE) out-
lined the most recent UK treatment guidelines for people with type
2 diabetes in 2015.12 Evidence-based, patient-specific education and
lifestyle modification should form the initial basis of treatment. If this
proves unsuccessful in controlling blood glucose levels (inadequate
control defined as a glycated haemoglobin [HbA1c] level of ≥7.5%
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[53 mmol/mol]) then metformin should be administered as a first-line
pharmacologic therapy, followed by intensification of therapy as the
disease progresses according to patient preferences and multifactorial
treatment targets. The combination of metformin with long-acting
basal insulin should be considered an essential therapy for patients
with advanced disease not achieving agreed HbA1c targets on current
antidiabetic medications.13 However, it has been reported that
approximately 64% of patients with type 2 diabetes on basal insulin
therapy experience inadequate glycaemic control, with 60% not
receiving intensified treatment in a timely manner.14,15 At this stage,
intensification to basal-bolus insulin therapy is typically recom-
mended. While efficacious in terms of reducing HbA1c, such a treat-
ment regimen is associated with weight gain and high risk of
hypoglycaemic episodes. Additionally, the multiple daily injections
required represent a more complex treatment regimen. These factors
have been linked to reduced patient adherence, leading to impaired
glycaemic control.5,16–21
A combination of basal insulin plus glucagon-like peptide-1 (GLP-1)
receptor agonists represents an alternative to basal-bolus insulin for
patients with type 2 diabetes not achieving targets on basal insulin alone.
Such a combination takes advantage of the complementary mechanisms
of action of the 2 interventions, as GLP-1 receptor agonists mitigate
many of the undesirable side effects associated with basal insulin ther-
apy, particularly weight gain and hypoglycaemia.22 Insulin degludec/lira-
glutide (IDegLira) combines insulin degludec, a basal insulin therapy with
a half-life of more than 24 h, and liraglutide, a GLP-1 receptor agonist, in
a fixed-ratio, once-daily injection.23 The recent 26-week, non-inferiority,
treat-to-target DUAL VII trial compared the efficacy and safety of IDe-
gLira versus a typical basal-bolus therapy (BBT) in patients with inade-
quate glycaemic control (HbA1c 7.0%-10.0%) on basal insulin therapy
(20-50 IU insulin glargine U100 plus metformin).24 BBT consisted of
basal insulin glargine U100 (Lantus®) plus bolus insulin aspart
(NovoRapid®), with any subsequent mention of insulin glargine U100
and insulin aspart referring to these formulations, unless otherwise
stated. The patient population comprised 506 adults with mean age
58.3 years, mean baseline body mass index (BMI) 31.7 kg/m2, mean
duration of diabetes 13.2 years, mean HbA1c 8.22% (66 mmol/mol), and
mean pre-trial insulin glargine U100 dose 33.4 IU. Following adjustment
for differences between the trial arms, IDegLira and BBT were associated
with similar HbA1c reductions (1.48% [16.2 mmol/mol] versus 1.46%
[16.0 mmol/mol], respectively), with an estimated treatment difference
(ETD) of −0.02% (−0.2 mmol/mol, 95% confidence interval [CI] −0.16%
to 0.12% [−1.7 to 1.2 mmol/mol]), as would be expected due to the
treat-to-target trial design. However, IDegLira was associated with a sta-
tistically significant reduction in BMI versus BBT after adjustment for dif-
ferences between the baseline characteristics of the trial arms (−0.35 kg/
m2 versus +0.96 kg/m2, ETD −1.31 [95% CI −1.53 to −1.08 kg/m2]).
Additionally, fewer non-severe hypoglycaemic episodes were observed
with IDegLira versus BBT (2.28 versus 10.91 episodes per patient per
year, a treatment ratio of 0.21 [95% CI 0.15-0.30]). Non-severe hypogly-
caemia was defined as an episode that is blood-glucose confirmed by a
plasma glucose value <3.1 mmol/L (56 mg/dL) with or without symp-
toms consistent with hypoglycaemia but does not meet the American
Diabetes Association (ADA) classification of a severe event.
Rates of diabetes-related complications would not be expected to
vary with IDegLira and BBT over the short term, due to the equivalent
level of glycaemic control. Instead, assessing the impact of aspects of
treatment that affect quality of life in the short term may provide
salient information for healthcare payers. The aim of the present anal-
ysis was, therefore, to evaluate the short-term cost-effectiveness of
intensifying therapy with IDegLira versus BBT in patients with type
2 diabetes inadequately controlled on basal insulin therapy from a
healthcare payer perspective in the UK setting.
2 | MATERIALS AND METHODS
2.1 | Model overview
A cost-utility model was developed in Microsoft Excel to evaluate
clinical and economic outcomes associated with IDegLira and BBT
with insulin glargine U100 plus insulin aspart over a 1-year time hori-
zon. The model accounted for pharmacy costs, including medication
acquisition costs, required needles and self-monitoring of blood glu-
cose (SMBG) testing, and costs of clinical events, including hypogly-
caemic episodes. The model captured quality of life utilities associated
with severe and non-severe hypoglycaemic episodes, and changes in
BMI over 25 kg/m2, with a disutility relating to injection frequency
applied in a sensitivity analysis. The model reported outcomes in the
form of cost breakdowns (expressed in pounds sterling [GBP]), quality
of life benefits (measured in quality-adjusted life years [QALYs]) and
the incremental cost-effectiveness ratio (ICER) in terms of additional
cost per QALY gained with IDegLira treatment versus BBT. No dis-
counting was applied as outcomes were not projected beyond 1 year.
2.2 | Clinical events and disutilities
Rates of severe and non-severe hypoglycaemic episodes and changes
in BMI associated with IDegLira and BBT were taken from the DUAL
VII trial.24 After adjustment for variations in baseline characteristics
between the trial arms, IDegLira was associated with reduced fre-
quency versus BBT of both severe (0.0003 vs. 0.0011 episodes per
patient per year) and non-severe (2.28 vs. 10.91 episodes per patient
per year) hypoglycaemic episodes, with non-severe hypoglycaemia
defined as an episode that is blood-glucose confirmed by a plasma
glucose value <3.1 mmol/L (56 mg/dL) with or without symptoms
consistent with hypoglycaemia, but which does not meet the ADA
classification of a severe event (Table 1). Additionally, IDegLira was
associated with a mean reduction in BMI of 0.35 kg/m2 per patient, in
comparison with a mean increase in BMI of 0.96 kg/m2 per patient
for BBT (Table 1).
Disutilities per severe (−0.0620) and non-severe (−0.0050) hypo-
glycaemic episodes were taken from a publication by Evans et al.,
which used a time trade-off method with UK-specific data and valua-
tion of health states by the general population (as recommended by
NICE).25 A disutility of −0.0061 per 1 kg/m2 increase in BMI above
25 kg/m2 was taken from the widely-cited Cost of Diabetes in Europe
– Type 2 (CODE-2) study (Table 1).26
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2.3 | Medication resource use and costs
Mean daily doses of 40.1 dose steps for IDegLira, 52.7 IU for insulin
glargine U100 and 32.3 IU for insulin aspart were used, based on the
DUAL VII trial.24 Injection frequency was once daily with IDegLira and
4-times daily with insulin glargine U100 plus insulin aspart (1 dose of
insulin glargine U100 plus 3 bolus doses of insulin aspart), as this was
the most common dosing schedule in DUAL VII. Each injection was
assumed to be performed by a single, new needle, as recommended by
the Forum for Injection Technique (FIT).27 Patients receiving IDegLira
were assumed to use 1 SMBG test per day, compared with 4 per day
with BBT, as recommended in guidelines issued by Training, Research
and Education for Nurses in Diabetes-United Kingdom (TREND-UK).28
All costs were accounted from a healthcare payer perspective in
pounds sterling (GBP). Annual costs of medications (IDegLira, insulin
glargine U100 and insulin aspart), needles, and SMBG testing were
based on wholesale acquisition costs (Table 2).29 Direct costs associ-
ated with severe hypoglycaemic episodes were based on values
reported by Hammer et al., inflated to 2016 values using the Hospital &
Community Health Services (HCHS) index.30,31 Direct costs associated
with non-severe hypoglycaemic episodes were calculated using health-
care resource use reported by Chubb and Tikkanen, with updated unit
costs applied (from the Unit Costs of Health and Social Care by the
Personal Social Services Research Unit [PSSRU]), and SMBG acquisition
costs fromMIMS UK.29,31,32 No costs were applied to changes in BMI.
2.4 | Sensitivity analyses
A series of 1-way sensitivity analyses were performed to identify key
drivers of model outcomes. The upper and lower 95% CIs for the
ETDs in BMI and severe and non-severe hypoglycaemic episodes
were applied to assess the impact of alternative clinical inputs. Smaller
disutilities for hypoglycaemia, estimated at −0.0118 per severe epi-
sode and −0.0035 per non-severe episode by Currie et al., were
explored to assess the contribution of quality of life following these
events to modelled outcomes.33 Larger BMI disutilities of −0.0210
(from Ridderstråle et al.) and −0.0100 (from Lee et al.) per each
1 kg/m2 over 25 kg/m2 were used to give a greater impact to weight
changes in comparison with the conservative disutility applied in the
base case.34,35 Disutilities to capture the difference in injection fre-
quency with IDegLira and BBT were applied, with twice-daily injection
(comprising 1 basal and 1 bolus injection) and 4-times daily injection
(comprising 1 basal and 3 bolus injections) associated with utility dec-
rements of −0.0460 and −0.0700, respectively, versus once-daily
injection (this range of utility values reflects the variation of the BBT
dosing schedule within the DUAL VII trial).24,34 Alternative costs of
severe and non-severe hypoglycaemic episodes were sourced from a
publication by Parekh et al. using the Local Impact of Hypoglycaemia
Tool (LIHT), which estimated the cost per severe episode to be GBP
412.92 and the cost per non-severe episode to be GBP 11.41, com-
pared with GBP 419.60 and GBP 3.95 in the base case, respectively.36
Twice-daily injection (comprising 1 basal and 1 bolus dose) was
applied for BBT, and a scenario in which both needle and SMBG
costs were excluded was prepared to evaluate the importance of the
costs of consumables to cost-effectiveness outcomes. Finally, a
lower cost comparator (biosimilar insulin glargine [Abasaglar®],
approximately 15% less costly than first-to-market insulin glargine
U100 [Lantus]) was applied in the basal-bolus regimen with no
changes in clinical inputs. It was assumed that this biosimilar had the
same efficacy and safety as first-to-market insulin glargine U100,
but it should be noted that these treatments may not be identical,
and approval of the use of biosimilars by the European Medicines
Agency (EMA) does not involve any assessment or recommendation
regarding interchangeability.37 Further scenarios with biosimilar
insulin glargine were evaluated, with a twice-daily injection regimen
(1 basal and 1 bolus injection) with BBT, and needle and SMBG costs
excluded.
TABLE 1 Summary of clinical event rates and disutilities used in the
base case analysis
Input description
Input for
IDegLira
Input for insulin glargine
U100 plus insulin aspart
Clinical event rates
Non-severe
hypoglycaemic
episodes (per patient
per year)
2.28 10.91
Severe hypoglycaemic
episodes (per patient
per year)
0.0003 0.0011
Change from baseline in
BMI (kg/m2)
−0.35 +0.96
Disutilities
Disutility per non-severe
hypoglycaemic episode
−0.0050
Disutility per severe
hypoglycaemic episode
−0.0620
Disutility per 1 kg/m2
increase in BMI over
25 kg/m2
−0.0061
Abbreviation: BMI, body mass index. Clinical event rates were taken from
the DUAL VII trial.24 Disutilities for hypoglycaemia and increases in BMI
were sourced from publications by Evans et al. and Bagust and Beale,
respectively.25,26 Non-severe hypoglycaemia was defined as an episode
that is blood-glucose confirmed by a plasma glucose value <3.1 mmol/L
(56 mg/dL) with or without symptoms consistent with hypoglycaemia but
which does not meet the ADA classification of a severe event.
TABLE 2 Summary of unit costs used in the base case
Clinical event costs Cost per episode (GBP)
Non-severe hypoglycaemia 3.95
Severe hypoglycaemia 419.60
Pharmacy costs
Pack
price (GBP)
Pack
contents
IDegLira 95.53 900 dose
steps
Insulin glargine U100 (Lantus®) 37.77 1500 IU
Insulin aspart (NovoRapid®) 30.60 1500 IU
BD MicroFine Ultra™ 4 mm/32 G
needles
9.69 100 needles
SMBG test strips (Aviva) 16.09 50 strips
SMBG lancets (FastClix) 5.90 204 lancets
Cost of non-severe hypoglycaemia was calculated using a combination of
sources.29,31,32 Cost of severe hypoglycaemia was calculated using data
published by Hammer et al. and Curtis and Burns.30,31 All pharmacy costs
were sourced from MIMS UK in April 2018.29
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3 | RESULTS
3.1 | Base case analysis
IDegLira was associated with an annual improvement of 0.0512 QALYs
versus BBT. This was driven by fewer non-severe hypoglycaemic
events (resulting in a gain of 0.0432 QALYs) and benefits in BMI
(resulting in a gain of 0.0080 QALYs) over the 1-year time horizon of
the analysis (Table 3). IDegLira was associated with a higher direct cost
than BBT (a total difference of GBP 303) resulting from higher acquisi-
tion costs (a cost increase of GBP 828). However, this was partially
offset by cost savings associated with avoidance of hypoglycaemic
episodes (cost savings of GBP 34), reduced needle use (cost savings of
GBP 106) and reduced SMBG resource use (cost savings of GBP 384)
(Figure 1). The combination of clinical and cost outcomes to assess
cost-effectiveness resulted in an ICER of GBP 5924 per QALY gained
for IDegLira versus BBT with insulin glargine U100 plus insulin aspart
for the treatment of patients with type 2 diabetes not achieving
glycaemic targets on basal insulin.
3.2 | Sensitivity analyses
ICERs remained below the UK willingness-to-pay threshold of
GBP 20 000 per QALY gained in all sensitivity analyses (Table 4).38,39
Application of the upper and lower 95% CIs for BMI and hypoglycae-
mia ETDs resulted in only small changes in the difference in quality of
life reported from the base case, with upper and lower limits for the
BMI ETD giving ICERs of GBP 5773 and GBP 6091 per QALY gained,
respectively. For hypoglycaemic episodes, the differences were
slightly greater, with the ICER falling to GBP 5524 per QALY gained
for the upper limit and increasing to GBP 6644 per QALY gained for
the lower limit.
Use of the smaller hypoglycaemia disutilities resulted in a reduced
quality of life benefit with IDegLira (+0.0382 QALYs), and the ICER
increasing slightly to GBP 7938 per QALY gained. The larger BMI dis-
utilities led to decreased ICERs of GBP 4289 and GBP 5387 per QALY
gained when the Ridderstråle et al. and Lee et al. disutilities were
applied, respectively. Both were driven by a greater quality of life ben-
efits with IDegLira. Hypoglycaemic event costs calculated using the
LIHT resulted in a decreased cost difference of GBP 239, giving an
ICER of GBP 4667 per QALY gained.
Application of the disutility for a 4-times daily injection frequency
for BBT (comprising 1 basal and 3 bolus doses) gave by far the largest
difference in quality of life seen throughout sensitivity analyses
(an increase of 0.1212 QALYs with IDegLira), resulting in the lowest
reported ICER of GBP 2503 per QALY gained. Assuming that patients
in the BBT arm used only twice-daily injections (comprising 1 basal
and 1 bolus injection) resulted in an increased cost difference of GBP
630, leading to an ICER of GBP 12 311 per QALY gained. Exclusion of
needle and SMBG testing costs increased the cost difference even
further to GBP 794, with the ICER also increasing to GBP 15 505 per
QALY gained.
The biggest variation in costs was seen with the use of a lower-
cost comparator, biosimilar insulin glargine, in the BBT arm with nee-
dle and SMBG costs excluded, with the cost difference increasing to
GBP 826, leading to an ICER of GBP 16 128 per QALY gained for
IDegLira versus BBT. The use of biosimilar glargine with no changes in
injection frequency and with a twice-daily injection regimen (compris-
ing 1 basal and 1 bolus dose) had a smaller impact, with ICERs of GBP
6548 and GBP 12 935 per QALY gained, respectively.
4 | DISCUSSION
The present analysis found that IDegLira was associated with an ICER
of GBP 5924 per QALY gained versus BBT with insulin glargine U100
plus insulin aspart. This falls below the willingness-to-pay threshold of
GBP 20 000 per QALY gained in the UK.38,39 Therefore, IDegLira was
considered to be cost-effective versus BBT with insulin glargine U100
plus insulin aspart for the management of patients with type 2 diabe-
tes in patients experiencing inadequate glycaemic control on a basal
insulin regimen in the UK. Quality of life was improved by a significant
decrease in non-severe hypoglycaemic episodes and a reduction,
rather than an increase, in BMI. Cost increases were driven predomi-
nantly by the higher acquisition cost of IDegLira, but this was partially
offset by cost savings associated with reduced use of needles, less
SMBG testing, and fewer hypoglycaemic episodes (Figure 1). Avoid-
ance of non-severe hypoglycaemic episodes was the largest contribu-
tor to reduced clinical event costs as, while they are less costly than
severe episodes, they occur much more frequently (Figure 1). IDegLira
remained cost-effective in all sensitivity analyses.
Previous studies have demonstrated the efficacy and safety of
insulin degludec and liraglutide for the treatment of patients with type
2 diabetes.40,41 These treatments have complementary modes of
action, as GLP-1 receptor agonists have been shown to mitigate
adverse events associated with basal insulin therapy, such as weight
gain and high risk of hypoglycaemia.22 This was also seen in the DUAL
VII trial, with equivalent reductions in HbA1c (the primary endpoint
for the trial) reported for IDegLira and BBT, and the only differences
arising in secondary endpoints. BBT is a more complex treatment regi-
men requiring multiple daily injections, and was associated with an
increased risk of hypoglycaemia and weight gain, which have all been
shown to reduce patient adherence and quality of life.5,16,42,43
Reduced patient adherence, in turn, may lead to impaired glycaemic
control and extra economic burden in real-world clinical practice
(as opposed to the controlled, clinical trial setting of the DUAL VII
TABLE 3 Utility benefit per patient with IDegLira versus insulin
glargine U100 plus insulin aspart
Aspect of care
Utility benefit with IDegLira
(QALYs)
Non-severe hypoglycaemic episodes
avoided
+0.0432
Severe hypoglycaemic episodes
avoided
+0.0001
Changes in BMI +0.0080
Total +0.0512
Abbreviations: BMI, body mass index; QALYs, quality-adjusted life years.
Non-severe hypoglycaemia was defined as an episode that is
blood-glucose confirmed by a plasma glucose value <3.1 mmol/L (56 mg/
dL) with or without symptoms consistent with hypoglycaemia but which
does not meet the ADA classification of a severe event.
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study).16,18,19 Further studies are needed to evaluate any long-term,
real-world difference in patient adherence between IDegLira and BBT
and any subsequent clinical impact that these differences may have.
The rationale for the comparison with BBT was based on the
common treatment paradigm of diabetes, whereby patients typically
intensify treatment to BBT following failure on basal insulin (with or
without additional oral antidiabetic medications), and on the recent
DUAL VII clinical trial, which directly compared IDegLira with BBT in
this patient population.13,24 There is no current uniform national or
international consensus for the optimal treatment regimen in type
2 diabetes, including the intensification steps beyond monotherapy,
the ideal combination when basal insulin is introduced, and the
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FIGURE 1 Summary of total costs per patient per year with IDegLira and insulin glargine U100 plus insulin aspart.
Abbreviations: GBP, pounds sterling; SMBG, self-monitoring of blood glucose
TABLE 4 Sensitivity analyses results
Analysis
Difference in quality of life per patient
per year (QALYs)
Difference in costs per patient per
year (GBP)
ICER (GBP per QALY
gained)
Base case +0.0512 +303 5924
Upper 95% CI of BMI ETD +0.0525 +303 5773
Lower 95% CI of BMI ETD +0.0498 +303 6091
Upper 95% CI of hypoglycaemia ETD +0.0544 +301 5524
Lower 95% CI of hypoglycaemia ETD +0.0462 +307 6644
Currie et al hypoglycaemia disutilities33 +0.0382 +303 7938
Ridderstråle et al BMI disutility34 +0.0707 +303 4289
Lee et al BMI disutility35 +0.0563 +303 5387
Disutility associated with increased
injection frequency applied34
+0.1212 +303 2503
Twice daily injection in basal-bolus arm +0.0512 +630 12 311
Parekh et al LIHT hypoglycaemic
episode costs36
+0.0512 +239 4667
Needle and SMBG costs excluded +0.0512 +794 15 505
Biosimilar glargine in basal-bolus arm +0.0512 +335 6548
Biosimilar glargine and twice-daily
injection in basal-bolus arm
+0.0512 +662 12 935
Biosimilar glargine in basal-bolus arm
and needle and SMBG costs excluded
+0.0512 +826 16 128
Abbreviations: BMI, body mass index; CI, confidence interval; ETD, estimated treatment difference; GBP, pounds sterling; ICER, incremental
cost-effectiveness ratio; LIHT, Local Impact of Hypoglycaemia Tool; QALYs, quality-adjusted life years; SMBG, self-monitoring of blood glucose.
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appropriate medications to include in tailored, individualised therapy.
IDegLira could therefore offer a viable treatment option for a variety
of patients. However, the present analysis only suggests that IDegLira
is a cost-effective alternative in patients with inadequate glycaemic
control on a basal insulin regimen compared with BBT, and assertions
of cost-effectiveness at other stages in the treatment paradigm can-
not be definitively stated without further study.
One advantage of this short-term analysis is its simplicity and
transparency. Clinical inputs, disutilities and cost values can be easily
varied, and the impact of each parameter on quality of life can be
readily assessed. Outputs can also be easily explained to patients,
allowing informed therapy selection. The analysis is easy to replicate
without requiring programming expertise or access to proprietary
models of type 2 diabetes (such as the IQVIA CORE Diabetes Model).
In contrast with long-term models of type 2 diabetes, rates of
complications were not included, as they were not expected to vary
over the short-term time horizon of the analysis.44–46 Furthermore,
glycaemic control, a key driver of rates of diabetes-related complica-
tions, was equivalent in both arms. However, rates of diabetes-related
complications can also be influenced by blood pressure, BMI and
serum lipid levels, and IDegLira was associated with improvements in
all of these risk factors versus BBT in the DUAL VII trial.24 Therefore,
it would be expected that complication rates would decrease with
long-term IDegLira treatment.4,47,48 The present model is intended to
allow for a relatively quick but informative analysis that can comple-
ment, rather than replace, conventional long-term diabetes modelling,
which typically projects outcomes (including microvascular and macro-
vascular complications and their associated impacts on costs and qual-
ity of life) over patient lifetimes.49
A limitation of the analysis is the reliance on non-UK-specific patient
data, as the participants of the DUAL VII study were recruited outside of
the UK. However, it is common practice to adapt clinical trial data from
multinational cohorts to country-specific analyses, with this methodol-
ogy found throughout the published literature.45,46,50–52 Moreover, the
effect of IDegLira and BBT would not be expected to vary across the dif-
ferent country settings included in the DUAL VII trial and the UK.
A further limitation is the application of treatment effects for
52 weeks, as the DUAL VII trial concluded after 26 weeks. However,
treatment effects displayed stability over the course of the DUAL VII trial,
with benefits seen at the start maintained for the full trial duration. Addi-
tional studies of diabetes medications have also shown that treatment
effects observed at 26 weeks are maintained at 52 weeks.53 Therefore, it
can be reasonably assumed that the benefits observed with IDegLira and
BBT would be maintained over a 52-week treatment course.
Across a wide range of sensitivity analyses, ICERs remained under
the willingness-to-pay threshold of GBP 20 000 per QALY in the
UK.38,39 Sensitivity analyses identified the importance of needle and
SMBG costs in driving outcomes, as removing these costs from the
analysis increased the ICER to GBP 15 505 per QALY gained for IDe-
gLira versus BBT (the second largest increase seen across the sensitiv-
ity analyses). Removal of these costs also contributed to the largest
increase in the ICER, seen when these costs were excluded and the
cost of biosimilar insulin glargine was applied in the BBT arm. Addi-
tionally, including a disutility for the increased 4-times daily injection
frequency associated with BBT (comprising 1 basal and 3 bolus doses)
resulted in the biggest decrease in the ICER, falling to GBP 2503 per
QALY gained. These data indicate that injection frequency is associ-
ated with a potentially important quality-of-life burden, concurring
with previous studies displaying patient preference for less complex
treatment regimens.16 The exclusion of a disutility for injection fre-
quency from the base case analysis reinforces the conservative nature
of the analysis, with IDegLira considered cost-effective despite this.
Application of upper and lower 95% CI for ETDs in BMI and hypogly-
caemia for IDegLira and BBT resulted in only a minor change in ICERs
(all within GBP 750 of the base case estimate), indicating the analysis
is robust to plausible changes in the clinical inputs.
In conclusion, IDegLira is a cost-effective alternative to BBT with
insulin glargine U100 plus insulin aspart for patients with type 2 diabetes
inadequately controlled on basal insulin in the UK. As the recent DUAL
VII trial has shown, IDegLira offers equivalent reductions in HbA1c to
BBT but provides a less complex treatment regimen and is associated
with reduced risk of hypoglycaemic episodes and weight loss rather than
weight gain. Further studies are needed to assess the long-term cost-
effectiveness of IDegLira in the UK, but the present analysis suggests
that IDegLira is cost-effective versus BBT over a 1-year time horizon.
Conflict of interest
R. S. D. has received speaker and advisory board fees and support for
attendance at scientific meetings from Novo Nordisk Ltd. M. D. P. is
an employee of Novo Nordisk Ltd. X. Y. L. is an employee of Novo
Nordisk A/S. S. M. and B. H. are employees of Ossian Health Econom-
ics and Communications, which received consulting fees from Novo
Nordisk A/S to support preparation of the analysis.
Author contributions
Russell Drummond, Michelle Du Preez, Xin Ying Lee and Barnaby
Hunt contributed to the design of the present study. Michelle Du
Preez, Xin Ying Lee and Barnaby Hunt contributed to data collection.
Barnaby Hunt and Samuel Malkin conducted the analyses presented.
All authors were involved in writing the present manuscript.
ORCID
Samuel Malkin http://orcid.org/0000-0003-1306-7784
Barnaby Hunt http://orcid.org/0000-0001-5420-279X
REFERENCES
1. International Diabetes Federation (IDF). IDF Diabetes Atlas – 8th
Edition. Brussels, Belgium: International Diabetes Federation (IDF);
2017. http://www.diabetesatlas.org/across-the-globe.html. Accessed
December 4, 2017.
2. Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet.
2014;383(9933):1947-1948.
3. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes:
a long-term model. QJM. 2003;96(4):281-288.
4. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure
control and risk of macrovascular and microvascular complications in
type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive
blood-glucose control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
6 DRUMMOND ET AL.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year
follow-up of intensive glucose control in type 2 diabetes. N Engl J
Med. 2008;359:1577-1589.
7. Ismail-Beigi F, Craven T, Banerji MA, et al. ACCORD trial group. Effect
of intensive treatment of hyperglycaemia on microvascular outcomes
in type 2 diabetes: an analysis of the ACCORD randomised trial. Lan-
cet. 2010;376:419-430.
8. ADVANCE Collaborative Group. Intensive blood glucose control and
vascular outcomes in patients with type 2 diabetes. N Engl J Med.
2008;358:2560-2572.
9. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose
control and vascular complications in veterans with type 2 diabetes. N
Engl J Med. 2009;360:129-139.
10. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascu-
lar disease in types 1 and 2 diabetes mellitus: meta-analysis of ran-
domized trials. Am Heart J. 2006;152(1):27-38.
11. Control Group. Intensive glucose control and macrovascular outcomes
in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298.
12. National Institute for Health and Care Excellence (NICE). NICE Guide-
lines 28. Type 2 Diabetes in Adults: Management. London, UK: National
Institute for Health and Care Excellence (NICE); 2015. http://www.
nice.org.uk/guidance/ng28. Accessed October 9, 2017.
13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hypergly-
cemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes
Care. 2015;38:140-149.
14. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A,
Esposito K. Efficacy of insulin analogs in achieving the hemoglobin
A1c target of <7% in type 2 diabetes: meta-analysis of randomized
controlled trials. Diabetes Care. 2011;34(2):510-517.
15. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insu-
lin therapy in patients with type 2 diabetes mellitus: beyond basal
insulin. Diabet Med. 2012;29(7):e13-e20.
16. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin
adherence behaviours and barriers in the multinational global attitudes
of patients and physicians in insulin therapy study. Diabet Med. 2012;
29(5):682-689.
17. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P,
Gonder-Frederick L. A critical review of the literature on fear of hypo-
glycemia in diabetes: implications for diabetes management and
patient education. Patient Educ Couns. 2007;68(1):10-15.
18. Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of
weight worry in the multinational diabetes attitudes, wishes and needs
study. Curr Med Res Opin. 2009;25(8):1985-1993.
19. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its asso-
ciation with glycaemic control in patients with type 2 diabetes. QJM.
2007;100(6):345-350.
20. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type
2 diabetes treatment-related attributes. Qual Life Res. 2007;16(7):
1251-1265.
21. Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A.
Utilities and disutilities for attributes of injectable treatments for type
2 diabetes. Eur J Health Econ. 2011;12(3):219-230.
22. Anderson SL, Trujillo JM. Basal insulin use with GLP-1 receptor ago-
nists. Diabetes Spectr. 2016;29(3):152-160.
23. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal
insulin once a day: a systematic review. Diabetes Metab Syndr Obes.
2012;5:191-204.
24. Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira
versus basal-bolus insulin therapy in patients with type 2 diabetes
uncontrolled on metformin and basal insulin; DUAL VII randomized
clinical trial. Diabetes Care. 2018;41:1009-1016.
25. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life
associated with daytime and nocturnal hypoglycaemic events: a time
trade-off survey in five countries. Health Qual Life Outcomes. 2013;
11(1):90.
26. Bagust A, Beale S. Modelling EuroQol health-related utility values for
diabetic complications from CODE-2 data. Health Econ. 2005;14(3):
217-230.
27. The Forum for Injection Technique (FIT). Diabetes care in the UK: The
First UK Injection Technique Recommendations. 2nd ed. Oxford, UK:
Becton, Dickinson UK Ltd; 2011. http://www.fit4diabetes.com/
files/2613/3102/3031/FIT_Recommendations_Document.pdf. Accessed
November 13, 2017.
28. TREND-UK. Blood Glucose Monitoring Guidelines Consensus Document.
Version 2.0. Brixworth, UK: TREND-UK; 2017. http://trend-uk.org/
wp-content/uploads/2017/02/170106-TREND_BG_FINAL.pdf. Accessed
November 13, 2017.
29. Database of prescription and generic drugs, clinical guidelines. MIMS
UK. Twickenham, UK: Haymarket Media Group; 2018. https://www.
mims.co.uk. Accessed April 26, 2018.
30. Hammer M, Lammert M, Mejías SM, Kern W, Frier BM. Costs of man-
aging severe hypoglycaemia in three European countries. J Med Econ.
2009;12(4):281-290.
31. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Personal
Social Services Research Unit, University of Kent, Canterbury.
32. Chubb B, Tikkanen C. The cost of non-severe hypoglycaemia in
Europe. Value Health. 2015;18(7):A611.
33. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P.
Multivariate models of health- related utility and the fear of hypogly-
caemia in people with diabetes. Curr Med Res Opin. 2006;22(8):
1523-1534.
34. Ridderstråle M, Evans LM, Jensen HH, et al. Estimating the impact of
changes in HbA1c, body weight and insulin injection regimen on
health related quality-of-life: a time trade off study. Health Qual Life
Outcomes. 2016;14:13.
35. Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU,
Kennedy-Martin T, Currie CJ. Evaluation of the association between
the EQ-5D (health-related utility) and body mass index (obesity) in
hospital-treated people with Type 1 diabetes, Type 2 diabetes and
with no diagnosed diabetes. Diabet Med. 2005;22:1482-1486.
36. Parekh WA, Ashley D, Chubb B, Gillies H, Evans M. Approach to
assessing the economic impact of insulin- related hypoglycaemia using
the novel local impact of hypoglycaemia tool. Diabet Med. 2015;32(9):
1156-1166.
37. European Medicines Agency and the European Commission. Biosimi-
lars in the EU: Information guide for healthcare professionals. London,
UK: European Medicines Agency; 2017. http://www.ema.europa.eu/
docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf.
Accessed June 13, 2018.
38. National Institute for Health and Care Excellence. Social Value Judge-
ments – Principles for the Development of NICE Guidance. 2nd ed. Lon-
don, UK: National Institute for Health and Care Excellence (NICE);
2008. https://www.nice.org.uk/Media/Default/About/what-we-do/
Research-and-development/Social-Value-Judgements-principles-for-
the-development-of-NICE-guidance.pdf ed. Accessed November
14, 2017.
39. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness thresh-
old: what it is and what that means. Pharmacoeconomics. 2008;26(9):
733-744.
40. Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of
insulin degludec given in variable once-daily dosing intervals com-
pared with insulin glargine and insulin degludec dosed at the same
time daily: a 26-week, randomized, open-label, parallel-group,
treat-to-target trial in individuals with type 2 diabetes. Diabetes Care.
2013;36(4):858-864.
41. Nauck M, Frid A, Hermansen K, et al. the LEAD-2 Study Group. Effi-
cacy and safety comparison of liraglutide, glimepiride, and placebo, all
in combination with metformin, in type 2 diabetes: the LEAD
(Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care.
2009;32(1):84-90.
42. Walz L, Pettersson B, Rosenqvist U, Deleskog A, Journath G,
Wändell P. Impact of symptomatic hypoglycemia on medication
adherence, patient satisfaction with treatment, and glycemic control
in patients with type 2 diabetes. Patient Prefer Adherence. 2014;30(8):
593-601.
43. Grandy S, Fox KM, Hardy E. SHIELD Study Group. Association of
Weight Loss and Medication Adherence among Adults with Type
2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation
and management of risk factors Leading to Diabetes). Curr Ther Res
Clin Exp. 2013;75:77-82.
44. Hunt B, Mocarski M, Valentine WJ, Langer J. Evaluation of the
long-term cost-effectiveness of IDegLira versus liraglutide added to
DRUMMOND ET AL. 7
basal insulin for patients with type 2 diabetes failing to achieve glyce-
mic control on basal insulin in the USA. J Med Econ. 2017;20(7):
663-670.
45. Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira versus insulin
glargine U100: a long-term cost-effectiveness analysis in the US set-
ting. Diabetes Ther. 2017;8(3):531-544.
46. Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC,
Montagnoli R. Long-term cost-effectiveness of two GLP-1 receptor
agonists for the treatment of type 2 diabetes mellitus in the Italian set-
ting: Liraglutide versus lixisenatide. Clin Ther. 2017;39(7):1347-1359.
47. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Mul-
tifactorial intervention and cardiovascular disease in patients with
type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
48. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a mul-
tifactorial intervention on mortality in type 2 diabetes. N Engl J Med.
2008;358(6):580-591.
49. American Diabetes Association Consensus Panel. Guidelines for com-
puter modeling of diabetes and its complications. Diabetes Care. 2004;
27(9):2262-2265.
50. Johnston R, Uthman O, Cummins E, et al. Canagliflozin, dapagliflozin
and empagliflozin monotherapy for treating type 2 diabetes: system-
atic review and economic evaluation. Health Technol Assess. 2017;
21(2):1-218.
51. Mezquita-Raya P, Darbà J, Ascanio M, Ramírez de Arellano A.
Cost-effectiveness analysis of insulin degludec compared with insulin
glargine u100 for the management of type 1 and type 2 diabetes mel-
litus - from the Spanish National Health System perspective. Expert
Rev Pharmacoecon Outcomes Res. 2017;17(6):587-595.
52. Russell-Jones D, Heller SR, Buchs S, Sandberg A, Valentine WJ,
Hunt B. Projected long-term outcomes in patients with type 1 diabetes
treated with fast-acting insulin aspart vs conventional insulin aspart in
the UK setting. Diabetes Obes Metab. 2017;19(12):1773-1780.
53. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagli-
flozin over 52 weeks in patients with type 2 diabetes on background
metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):
467-477.
How to cite this article: Drummond R, Malkin S, Du Preez M,
Lee XY, Hunt B. The management of type 2 diabetes with
fixed-ratio combination insulin degludec/liraglutide (IDegLira)
versus basal-bolus therapy (insulin glargine U100 plus insulin
aspart): A short-term cost-effectiveness analysis in the UK set-
ting. Diabetes Obes Metab. 2018;1–8. https://doi.org/10.
1111/dom.13375
8 DRUMMOND ET AL.
